Komfoderm M2, cream 30 g

A product with anti-inflammatory and keratolytic effect for external use.

Indications

Inflammatory skin diseases sensitive to therapy with topical glucocorticosteroids and accompanied by impaired keratinization:

– atopic dermatitis, neurodermitis;

– true eczema;

– microbial eczema;

– simple contact dermatitis;

– allergic (contact) dermatitis;

– dyshidrotic eczema.

Active ingredient

Composition

100 g cream contains:

Active substances:methylprednisolone aceponate 100 mg; urea 2 g;

Auxiliary substances: liquid paraffin (vaseline oil) – 15 g, propylene glycol – 5 g, polysorbate 80 – 1 g, carbomer interpolymer (type A) – 1 g, trometamol – 400 mg, methyl parahydroxybenzoate – 100 mg, purified water – up to 100 g.

How to take, the dosage

Over the top

The product is applied once daily in a thin layer to the affected areas of skin. In general, continuous daily treatment with Comfoderm® M2 should not exceed 12 weeks. In patients with facial skin lesions the course of treatment should not exceed 5 days.

Interaction

Interaction of the drug with other medicinal products has not been identified, but it should be noted that simultaneous use of the drug Comfoderm ® M2 with other ointments or creams may lead to increased resorption of their constituent drugs.

Special Instructions

In the presence of bacterial complications and/or dermatomycosis, specific antibacterial and/or antifungal treatment is required in addition to therapy with Comfoderm® M2.

The drug is not intended for use in ophthalmology. Avoid contact of the drug with the eyes and mucous membranes.

As with systemic glucocorticoids, glaucoma may develop with external use of GCS (e.g., after high doses, due to very long use, use of occlusive dressings or application to the skin around the eyes). Atrophic changes may develop on the face more often than on other body surfaces after long-term treatment with GCS for external use.

Influence on the ability to drive and operate machinery

Have not been identified.

Contraindications

– hypersensitivity to the ingredients of the drug;

– tuberculosis or syphilitic process in the area of application;

– viral diseases (e.g., chicken pox, shingles);

– rosacea, perioral dermatitis in the area of application;

– areas of skin with signs of reaction to vaccination;

– children under 18 years of age.

Side effects

Very rarely (less than 0.01% of cases) local reactions such as itching, burning, erythema, formation of vesicular rash may be observed.

If the drug is used for more than 4 weeks and/or over 10% or more of the body surface area, the following reactions may occur: skin atrophy, telangiectasia, stretch marks, acneiform skin changes, and systemic effects due to absorption of the corticosteroid.

In rare cases (0.01%-0.1%) folliculitis, hypertrichosis, perioral dermatitis, depigmentation of the skin and allergic reactions to one of the components of the drug may be observed.

Overdose

Symptoms:Skin atrophy (thinning of the skin, telangiectasia, stretch marks) may develop with excessive and/or intensive topical use of GCS.

Treatment:In case of signs of skin atrophy, the drug should be discontinued.

Similarities